Semaglutide for the treatment of cognitive dysfunction in major depressive disorder
Tschop recounted his research with DiMarchi and that of others while he accepted the 2023 Banting Medal for Scientific Achievement at the 2023 American Diabetes Association Scientific Sessions.5 The FDA approved the first GLP-1 agonist, twice-a-day Byetta (exenatide), in 2005.1 Since then, several newer and more powerful medications in the GLP-1 agonist class, such as liraglutide and semaglutide, have received FDA approval for type 2 diabetes, with a higher dose of semaglutide FDA approved for weight loss.2 In mid-2022, the first dual agonist, tirzepetide (a combination of a GLP-1 agonist and a GIP), was FDA approved for type 2 diabetes
Individuals with pre-existing health issues such as liver disease, kidney problems, or those undergoing chemotherapy should be especially cautious
International Distribution and Global Supply Considerations The stability characteristics of Retatrutide Raw Powder make it suitable for international distribution to pharmaceutical markets in North America, Europe, Asia, and emerging economies worldwide
An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection